In the immune system, neuropilins (NRPs), including NRP-1 and NRP-2, are expressed in thymocytes, dendritic cells, regulatory T cells and macrophages. Their functions on immune cells around the neoplastic cells vary into pro-angiogenesis, tumor progression and antiangiogenesis according to their ligands. Even though NRPs expression on malignant tumors and immune system has studied, a PubMed-based literature query did not yield any articles describing NRPs expression on tissue-specific macrophages. The aims of this study were (i) to detect NRPs expression on tissue-specific macrophages in the brain, liver, spleen, lymph node and lung; (ii) to observe NRPs expression in classes of macrophages, including alveolar macrophages (AMs), bronchial macrophages (BMs), interstitial macrophages (IMs), intravascular macrophages (IVMs) and macrophage subsets (M1, M2 and Mox) in lung; and (iii) to detect the co-expression of NRPs and dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) in AMs. Both NRPs were specifically detected in AMs among tissue-specific macrophages by immunohistochemistry (IHC). NRPs mRNA expression levels were characterized in normal lung by reverse transcriptase polymerase chain reaction (RT-PCR) and in situ-polymerase chain reaction (in situ-PCR). The expression of both NRPs was detected in AMs, BMs and IVMs by IHC. The frequency of NRPs + AMs in lung tissue adjacent to the cancer margin was significantly higher than the frequencies in inflamed and normal lung tissue. Double and triple IHC demonstrated that NRPs are expressed on all macrophage subsets in lung. Double IHC showed co-expression of DC-SIGN and NRPs in AMs. This study demonstrated for the first time the specific expression of both NRPs in AMs among tissue-specific macrophages and their expression on M1, M2 and Mox macrophages. Furthermore, the possible origin of AMs from blood monocytes could be suggested from a co-expression of NRPs and DC-SIGN.
Introduction
with NRPs and DC-SIGN. However, no studies to date have described the co-expression of and the correlation between NRPs and DC-SIGN on alveolar macrophages.
The aims of this study were (i) to detect the expression of NRPs on tissue-specific macrophages in the brain, liver, spleen, lymph node and lung; (ii) to observe NRPs expression in classes of macrophages, including alveolar macrophages (AMs), bronchial macrophages (BMs), interstitial macrophages (IMs), intravascular macrophages (IVMs) and macrophage subsets (M1, M2 and Mox) in lung; and (iii) to detect the co-expression of NRPs and DC-SIGN in AMs.
Materials and Methods

Tissue specimens
To explore NRPs expression in tissue-specific macrophages, tissue specimens (n = 5) of brain, liver and lung tissues were obtained from remote to the cancer nest, whereas spleen and lymph node tissues (n = 5) were from the patients with reactive hyperplasia. To observe NRPs expression in classes and subsets of macrophages in lung, pulmonary tissues, including lung cancer tissue, tissue remote to the cancer nest (physiologically normal lung) and inflamed lung tissue were obtained from Yamagata University Hospital between 2009 and 2013 ( Table 1 ). All of the specimens were obtained under written consent from each patient. This study was approved by the Research Ethics Committee (H25-117) of Yamagata University Faculty of Medicine, Yamagata, Japan.
Tissues were fixed in buffered 10% formalin for 6-12 hours at room temperature, embedded in paraffin and used for single immunohistochemistry (IHC), double IHC, triple IHC, double immunofluorescence (IF), single IHC after single IF, reverse transcriptase polymerase chain reaction (RT-PCR) and in situ-polymerase chain reaction (in situ-PCR).
Single immunohistochemistry (Single IHC)
IHC was performed using antibodies against NRP-1 (rabbit polyclonal, Abcam, Cambridge, United Kingdom), NRP-1 (A-12, mouse IgG1, Santa Cruz Biotechnology, CA, USA), NRP-1 (rabbit polyclonal, Invitrogen, Frederick, MD, USA), NRP-2 (goat polyclonal, R&D Systems, Minneapolis, MN, USA), CD68 (PG-M1, mouse IgG1κ, DAKO, Glostrup, Denmark), CD163 (10D6, mouse IgG1, NOVOCASTRA, Newcastle, United Kingdom), HO-1 (D-8, mouse IgG1, Santa Cruz Biotechnology) and DC-SIGN (rabbit polyclonal, IgG, Abcam). We used arterial, venous and lymphatic endothelia as positive controls for NRP-1 and NRP-2 [14] . Phosphatebuffered saline (PBS, 0.01 M, pH 7.4), Universal Negative Control-Mouse (N1698; DAKO) and Universal Negative Control-Rabbit (N1699; DAKO) were used as negative controls.
Three-micrometer-thick cut sections were deparaffinized. Endogenous peroxidase activity was blocked with methanol containing 0.3% hydrogen peroxide for 30 min on ice. Antigen retrieval was performed using EDTA (Antigen Retrieval Solution pH 9; Nichirei Biosciences, Tokyo, Japan) or citric acid (Antigen Retrieval Solution pH 6; IATRON LABORATORIES INC., Tokyo, Japan) in an autoclave (2 atmospheres, 121°C, 20 min) and 7 min for 3 times in a microwave. Sections were incubated with primary antibodies at room temperature overnight. The labeled streptavidin-biotin peroxidase method (UltraTech HRP Streptavidin-Biotin Detection system, PN IM2391; Immunotech, Marseille, France), Histofine SAB-PO (anti-goat) kit (Nichirei Biosciences, Tokyo, Japan) and EnVision+ System-HRP labeled polymer (anti-rabbit, DAKO, Carpinteria, CA, USA) were used. Positive reactions were detected as a brown coloration with 3,3'-diaminobenzidine tetrahydrochloride (DAB) (Dojindo, Kumamoto, Japan). Sections were then counterstained with hematoxylin. The expression levels of NRP-1 and NRP-2 in tissue-specific macrophages in brain, lung, liver, spleen and lymph node were confirmed with IHC on serial sections, including an antibody cocktail solution for CD68 and CD163.
Positive cells, as determined by IHC for NRP-1, NRP-2 and DC-SIGN, were counted as AMs in the alveolar space, BMs in the bronchial lumen or endobronchial area, IMs in the peribronchial area or interstitium and IVMs in the vascular lumen. NRP-1-and NRP-2-positive macrophages in alveolar space adjacent to lung cancer, in inflammatory alveolar space in inflamed lung and in alveolar space in lung tissue remote to the cancer nest were counted. Positive cells were counted in 10 areas in a high-power view field (HPF) by two experienced observers in a blinded manner.
Double immunohistochemistry (Double IHC)
Positive reaction of the first antibody was detected as a dark blue coloration with the 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/NBT) substrate system (DAKO), 
Double immunofluorescence (Double IF)
Immunofluorescence double staining using paraffin-embedded tissue sections was performed as previously described [15] . IF was performed using antibodies against NRP- 
Reverse transcriptase polymerase chain reaction (RT-PCR)
Formalin-fixed and paraffin-embedded tissues from the brain (n = 2), liver (n = 2), spleen (n = 2), lymph node (n = 2) and lung (n = 3) were used for mRNA detection by RT-PCR. mRNA was extracted with a WaxFree RNA™ RNA Extraction Kit (TrimGen, Sparks, MD, USA) according to the manufacturer's protocol. mRNA (< 5 μg) was used as a template for the synthesis of cDNA (20 μl) with a PrimeScript™ II 1 st strand cDNA Synthesis Kit (TAKARA BIOTECHNOLOGY, Shiga, JAPAN). Three microliters of cDNA was PCR-amplified utilizing EmeraldAmp 1 PCR Master Mix (TAKARA) and specific primers. The primer sequences were 5'-TGAGCCCTGTGGTTTATTCC-3' and 5'-CGTACTCCTCTGGCTTCTGG-3' for human NRP-1 (120 bp), 5'-GTGGTTCATCTTGACCTTGT-3' and 5'-ATTCTTCTTCTGCAA CCTCA-3' for human Nrp-2 (257 bp) [16, 17] and 5'-GCACCGTCAAGGCTGAGAAC-3' and 5'-TGGTGAAGACGCCAGTGGA-3' for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 137 bp) as the internal control. cDNA was amplified as follows: 94°C for 10 min; 40 cycles of 94°C for 30 sec, 57°C for 45 sec and 72°C for 30 sec; and 1 cycle of 72°C for 6 min in a Veriti™ 96 Well Thermal Cycler (Applied Biosystems, Foster city, CA, USA). Final PCR products were placed at 4°C until electrophoresis. We used primers for human NRP-1 designed by PrimerBank. The PCR products were electrophoresed in a 4% agarose gel and stained with ethidium bromide.
In situ-polymerase chain reaction (in situ-PCR)
We examined lung tissue remote to the cancer nest to detect the mRNA expression levels of NRP-1 and NRP-2 in AMs. The conditions used for in situ-PCR were as described elsewhere [18, 19] . Briefly, dewaxed and rehydrated 3-5 μm paraffin sections were fixed in 4% paraformaldehyde for 4 hours at room temperature. After fixation, the slides were incubated in pepsin (8 mg/ml) for 75 min at 37°C. After protein digestion, the slides were air-dried and incubated in DNase digestion solution (DNase I recombinant, RNase-free, Roche Diagnostics, Mannheim, Germany) at 37°C overnight.
After DNase digestion, a reverse transcriptase reaction was performed in the solution provided in the PrimeScript II cDNA synthesis kit (TAKARA) according to the manufacturer's protocol. Coverslips were placed over the solutions in the DNase digestion and reverse transcriptase reactions to prevent evaporation of the solutions. Slide sealers (TAKARA) were placed on the slides around the tissue prior to PCR.
The in situ-PCR reaction mix consisted of PCR buffer with 15 mM MgCl 2 , PCR digoxigenin (DIG) labeling mix, Taq DNA polymerase and primer pairs for each NRP-1 and NRP-2 (same primer pairs as RT-PCR). A total of 125 μl of PCR reaction mix was applied to the tissue sections, which were then sealed with slide sealers. Slides were placed into a MasterCycler 1 PCR thermal cycler (Eppendorf, Hamburg, Germany) for 1 cycle of 94°C for 10 min; 30 cycles of 94°C for 30 sec, 57°C for 45 sec and 72°C for 30 sec; and 1 cycle of 72°C for 6 min. The location of DIG incorporated into PCR amplicons was detected by an alkaline phosphatase assay using anti-DIG-alkaline phosphatase Fab fragments (1:100 dilution) (Roche Diagnostics), which were incubated with the samples for 30 min at 37°C. The in situ-PCR product was detected using a Vulcan fast red chromogen kit 2 (BIOCARE MEDICAL, Concord, CA, USA) and was counterstained with hematoxylin. Tissue sections without primers and without reverse transcriptase reactions were used as negative controls.
Statistical analysis
The Kruskal-Wallis test was performed for comparisons of IHC-positive cells and the different groups. The Mann-Whitney U-test was performed for the comparison of positive cells for each of the 2 groups. Data were analyzed using SPSS (Statistical Package for the Social Sciences) ver.13.0 software (SPSS Inc, Chicago, IL, USA) with the level of significance at p< 0.05. The correlation between NRP-1 and DC-SIGN was quantified using the Spearman rank correlation method and the Pearson correlation method.
Results
Expression of NRP-1 and NRP-2 on tissue-specific macrophages in the brain, lung, liver, spleen and lymph node
To investigate NRP-1 and NRP-2 expression in tissue-specific macrophages, single IHC for NRP-1 and NRP-2 and immunostaining with cocktail antibodies for CD68 and CD163 in serial tissue sections were performed. NRP-1 and NRP-2 were specifically expressed in AMs among tissue-specific macrophages (microglia in the brain, Kupffer cells in the liver, red pulp macrophages in the spleen and sinus histiocytes in the lymph node) (Figs 1 and 2 ). In addition, NRP-1 and NRP-2 expression was detected on neurons in brain tissue (Fig 1) . In lung tissue, NRP-1 expression was observed in the nuclei and cytoplasm of neutrophils, some reactive lymphocytes, plasma cell-like lymphocytes and respiratory epithelial and glandular epithelial cells. NRP-2 expression in lung tissue was observed in respiratory epithelial and glandular epithelial cells. Weak NRP-1 expression was observed in the cytoplasm of hepatocytes in liver tissue. In spleen and lymph node, NRP-1 expression was observed in some lymphocytes in the marginal and mantle zones of lymphoid follicles, plasma cell-like lymphocytes and some dendritic celllike cells. NRP-1 and NRP-2 expression was observed on lymphatic and vascular endothelial cells in brain, lung, liver, spleen and lymph nodes. NRP-1 antibodies from 3 different sources (Abcam, Santa Cruz Biotechnology, and Invitrogen) were tested on the above tissues, and all antibodies showed positive reactions with alveolar macrophages among tissue-specific macrophages (Fig 3) . However, the nuclei and cytoplasm of lymphocytes in the marginal and mantle zones of lymphoid follicles, plasma cell-like lymphocytes and some dendritic cell-like cells in spleen and lymph node showed positive reactions only with the NRP-1 antibody from Abcam. Further IHC in this study was performed using the NRP-1 antibody from Abcam.
NRP-1 and NRP-2 mRNAs expression in the brain, liver, spleen, lymph node and lung by RT-PCR and, NRP-1 and NRP-2 mRNA expression in AMs in the lung by in situ-PCR RT-PCR was performed to detect the presence of NRP-1 and NRP-2 mRNAs in the brain, liver, spleen, lymph node and lung. GAPDH mRNA (a housekeeping gene) was expressed in all cases. NRP-1 and NRP-2 mRNAs were expressed in all normal lung tissues. In addition, NRP-1 mRNA was detected in normal brain, liver, spleen and lymph node. However, NRP-2 mRNA was detected only in the normal brain in addition to normal lung (Fig 4A) .
To confirm the NRP-1 and NRP-2 mRNA expression levels in AMs, in situ-PCR was performed. By in situ-PCR, NRP-1 and NRP-2 mRNAs were observed in AMs in lung tissue remote to the cancer nest by coloration with Vulcan fast red stain (Fig 4B) . The factor that these NRP + cells are macrophages was confirmed by single immunohistochemistry for antibody cocktail solution of CD68 and CD163 in serial tissue sections. All alveolar macrophages are positive for CD68 and CD163 (Fig 3) .
NRP-1 and NRP-2 expression in classes of lung macrophages in physiologically normal lung
To observe NRP-1 and NRP-2 expression in lung macrophages in physiologically normal lung, single IHC for NRP-1 and NRP-2, and IHC for an antibody cocktail solution of CD68 and CD163 in serial tissue sections were performed. Almost all AMs expressed NRP-1 and NRP-2.
In addition, NRP-1 and NRP-2 were expressed in BMs (Fig 1) and IVMs (Fig 5) . However, NRP-1 and NRP-2 expression was not detected in IMs (data not provided). The frequency of NRP-1 and NRP-2 expression in AMs was significantly higher than that observed in IMs ( Table 2 ). The numbers of NRP-1 + and NRP-2 + BMs and IVMs were not included in this comparison because the counted areas containing positive cells were not sufficient to account for 10 areas.
Comparison of NRP-1 and NRP-2 expression in AMs in lung tissue adjacent to the cancer margin, inflamed lung and lung tissue remote to the cancer nest
To observe the numbers of NRP-1-and NRP-2-positive AMs in different lung conditions, IHC was performed for NRP-1 and NRP-2 in lung tissue adjacent to the cancer margin, tissue remote to the cancer nest (physiologically normal lung) and inflammatory lung tissue. NRP-1 and NRP-2 were expressed in AMs in lung cancer patients both with and without smoking habits. The frequency of NRP-1 + AMs in lung tissue adjacent to the cancer margin was significantly higher than the frequency of NRP-1 + AMs in inflamed lung and lung tissue remote to the cancer nest. In inflamed lung, the number of NRP-1 + AMs was higher than that of NRP-1 + AMs in lung tissue remote to the cancer nest. The frequencies of NRP-2 + AMs among these lung tissue types were the same as those for NRP-1 + AMs (Fig 6, Table 3 ). NRP-1 and NRP-2 expression was also observed in some lung cancer cells (data not provided).
The frequencies of NRP-1-and NRP-2-positive alveolar macrophages adjacent to small cell carcinomas (n = 3) were also significantly higher than the frequencies of NRP-1-and NRP-2-positive alveolar macrophages in inflamed lung and lung tissue remote to the cancer nest.
NRP-1 and NRP-2 expression in macrophage subsets of AMs in lung tissue adjacent to the cancer margin
To detect NRP-1 and NRP-2 expression in macrophage subsets in lung tissue adjacent to the cancer margin, double IHC, double IF and single IHC after single IF were performed. They revealed CD68, CD163 and HO-1 expression in both NRP-1 + and NRP-2 + AMs (Fig 7A) . Dou- (Fig 7B) .
Expression of and correlation between DC-SIGN and NRP-1 in AMs in lung tissue adjacent to the cancer margin
To observe the co-expression of DC-SIGN and NRP-1 in AMs, single and double IHC assays of NRP-1 and DC-SIGN were performed. DC-SIGN expression was also observed on AMs in lung tissue adjacent to the cancer margin. The number of DC-SIGN + AMs in lung tissue adjacent to the cancer margin was significantly higher than the number of DC-SIGN + AMs in lung tissue remote to the cancer nest (Table 4 , p< 0.05). Double IHC indicated that 95.8% of DC-SIGN + AMs co-expressed NRP-1 and 94.9% for NRP-2, in lung tissue adjacent to the cancer margin (Fig 7B) . The correlation between DC-SIGN and NRP-1 expression was quantified using the Spearman correlation method (R = 0.956, p< 0.01) and the Pearson correlation method (R = 0.919, p< 0.01). The co-localization of NRP-2 and DC-SIGN on AMs was also explored by double IF (Fig 7B) . The correlation between DC-SIGN and NRP-2 expression was also quantified using the Spearman correlation method (R = 0.948, p< 0.01) and the Pearson correlation method (R = 0.915, p< 0.01).
Discussion
In this study, NRP-1 and NRP-2 expression was examined on tissue-specific macrophages in the brain, liver, spleen, lymph node and lung by IHC. NRP-1 and NRP-2 expression was Physiologically normal lung (n = 5) 9.2 ± 3.8** , *** , # 8.9 ± 3.9** , *** , # * p< 0.01 significant between squamous cell carcinoma and inflamed lung; ** p< 0.01 significant between inflamed lung and physiologically normal lung; *** p< 0.01 significant between squamous cell carcinoma and physiologically normal lung; ‡ p< 0.05 significant between adenocarcinoma and inflamed lung and observed only in AMs among tissue-specific macrophages. mRNAs of NRP-1 and NRP-2 were detected in normal lung and brain by RT-PCR. Furthermore, the detection of NRP-1 mRNA in spleen and lymph node may be due to the presence of NRP-1 expression on lymphocytes, dendritic cells and plasma cell-like lymphocytes in the spleen and lymph node. The detection of NRP-1 mRNA in liver may be explained by the weak positivity observed in normal hepatocytes by IHC. NRP-1 and NRP-2 mRNAs were also detected in neurons the brain by IHC. Fujita H and co-workers investigated the presence of NRP-1 and NRP-2 by PCR, using rat brain [20] . However, there were no detectable amounts of NRP-2 mRNA in the liver, spleen and lymph node. The presence of NRP-1 and NRP-2 mRNAs in AMs was confirmed by in situ-PCR. Based on these data, NRP-1 and NRP-2 expression may differ in tissue-specific macrophages according to their origin.
In a steady state, it is thought that AMs are derived from local proliferating precursors. Under conditions other than steady state, AMs originate from blood monocytes. Tissue-specific macrophages from brain, liver and spleen are suggested to have differentiated from local proliferating precursors [13] . A study in mice described that AMs originate from fetal blood monocytes, microglia from yolk sac macrophages and intestinal macrophages from bone marrow monocytes [21] . Identification of NRP-1 and NRP-2 expression in intestinal macrophages was not performed in this study.
In the lung, there are three main classes of macrophages, namely BMs, AMs and IMs; IVMs are also present (monocytes in the inner sides of blood capillaries). BMs are isolated from induced sputum. AMs arise from circulating blood monocytes and are found in alveolar lumens. These macrophages provide a nonspecific innate defense mechanism. As has been previously reviewed, IMs are generally considered as antigen-presenting macrophages [22] . Some studies reviewed that BMs can also defined as unattached AMs in large airways and also AMs in bronchoalveolar lavage. [23, 24] . In this study, NRP-1 and NRP-2 were expressed in AMs, BMs and IVMs, but not in IMs. NRP-1 and NRP-2 expression increased in AMs under conditions of lung inflammation and lung cancer. These observations suggest that NRP-1 and NRP-2 may be related to the origin of AMs from blood monocytes (IVMs).
Generally, macrophages are divided into M1 and M2 subsets based upon their roles and profiles [25] . M1 macrophages are known to drive inflammation in response to intracellular pathogens, whereas M2 macrophages play a role in the phagocytosis of foreign pathogens and apoptotic cells [26, 27] . Broadly, M1 macrophages, also called classically activated macrophages, possess pro-inflammatory properties by the secretion of interleukin-17 (IL-17), reactive oxygen intermediates, proinflammatory cytokines such as tumor necrosis factor, IL-1β, IL-8 and monocyte chemoattractive protein (MCP)-1 and mediate host defenses against a variety of bacteria, protozoa and viruses. M2 macrophages, also called alternatively activated macrophages, possess anti-inflammatory functions (mostly suppression of the inflammatory response, neutralization of the Th2 response and immunosuppression) by the secretion of IL-10, IL-12 and nitric oxide and regulate wound healing. Anti-inflammatory functions and angiogenesis near tumor islets promote tumor survival and progression [22, 28] . Recently, Mox macrophages have been identified as a subset of macrophages. However, in vitro phagocytosis assays demonstrated that Mox macrophages are poor efferocytes and are only weakly able to phagocytose oxidized low-density lipoprotein (oxLDL), suggesting that Mox may not be able to effectively clear apoptotic cells and resolve inflammation in vivo [29, 30] . Mixed phenotypes and a phenotypic switch in macrophage populations over time, along with an association with pathology, have been suggested in previous reviews [31, 32] in lung tissue adjacent to the cancer margin suggested that AMs in lung tissue adjacent to lung cancer were mostly composed of M2 macrophages. In the tumor microenvironment, M1 macrophages can progressively differentiate to a regulatory phenotype and eventually become cells that share the characteristics of both regulatory and M2 macrophages [31] . In a previous study, increased NRP-1 and NRP-2 expression was observed during colony stimulating factor of macrophage (M-CSF)-driven differentiation of human monocytes into M2-like macrophages [34] . M2 macrophages and maturing monocytes under prolonged hypoxia can produce VEGF, which is also a ligand for NRP-1 and NRP-2, and can thus promote tumor progression and angiogenesis [35] . Since macrophages around tumor play a role in immune system for tumor progression and angiogenesis, NRPs expression on macrophages around tumor may give the pathway to tumor progression and angiogenesis. However, assessments of VEGF expression and its correlation with NRPs in AMs and blood monocytes were not performed in this study. Because DC-SIGN is naturally expressed in human dendritic cells, its expression is also increased upon M2 macrophage differentiation of alveolar macrophages induced by M-CSF [36] . Furthermore, blood monocytes and monocyte-derived dendritic cells express NRP-1 and DC-SIGN. However, there is no study about NRP-2 expression on blood monocytes and monocyte-derived dendritic cells on pubmed-based article search. In this study, 95.8% of DC-SIGN + AMs co-expressed NRP-1 and 94.9% for NRP-2, and there was a correlation between NRP + AMs and DC-SIGN + AMs adjacent to lung cancer. Because of the co-expression of NRPs and DC-SIGN in alveolar macrophages and the fact that NRPs is also expressed in intravascular macrophages (blood monocytes), NRPs and DC-SIGN may be suggested as their involvement in the differentiation of AMs from blood monocytes or transmigration of blood monocytes through the vascular endothelial junctions. Further investigations such as (a) factors influencing the expression of NRP-1 and NRP-2, (b) status of inflammatory response during inactivation of these factors, and (3) functional relation of these factors to DC-SIGN in M2 macrophages are suggested for future research.
Conclusion
In this study, the expression of both NRPs, specifically in AMs among tissue-specific macrophages, was observed for the first time. This study demonstrated that NRP-1 and NRP-2 are expressed on M1, M2 and Mox macrophages. Furthermore, co-localization of NRPs and DC-SIGN in alveolar macrophages from blood monocytes was described.
